Can a drug famous for making people "space out" actually be used to rebuild lost memories and reverse cognitive decline?

Does ketamine just numb the pain of depression, or can it actually regrow the brain's physical capacity to feel pleasure?

Does a psychiatric medication actually need to alter your consciousness to rewire your brain, or did the pharmaceutical industry accidentally engineer away the cure by trying to remove the "trip"?

What if the therapeutic "high" from an oral ketamine pill isn't actually caused by ketamine, but by a hidden metabolite manufactured by your liver?

For decades, treating bipolar depression meant risking the dangerous highs of mania, but a 2026 review reveals how ketamine's unique glutamate targeting offers rapid relief without waking the "manic bear."

Does anesthesia actually turn your brain off, or does it simply paralyze your body and erase your memory? We explore how ketamine and the "Isolated Forearm Technique" prove that consciousness persists even when the lights seem to be out.

Does adding talk therapy to ketamine infusions actually improve outcomes, or does its effectiveness depend entirely on a patient's age and childhood trauma?

A decade of research in one document: We explore the massive doctoral thesis of Jolien Veraart, which maps the "nightmare" of oral dosing, the hidden trap of liver tolerance (auto-induction), and the shift from "magic bullets" to neuroplasticity.

FDA-approved Spravato vs. generic ketamine: A new 2026 study pits the expensive "heavyweight" against the $42 challenger to see if the patent actually pays off in patient outcomes.

We celebrate our 50th episode by zooming in from brain circuits to the "nanoscopic world," exploring how ketamine repairs the precise molecular machinery of the synapse—realigning the "launch pads" and "receiver slots" that break down during depressi

For decades, the “Monoamine Dogma” ruled psychiatry: the brain was a chemical soup, depression was a lack of serotonin, and the cure was simply “filling the tank.” But there was always a glitch in the matrix—why did it take weeks for pills to work if the chemistry changed in hours? In this special 25th-anniversary episode, we review a retrospective paper from 2026 that traces the history of the “Neuroplastic Revolution.” We go back to the turning point: the accidental discovery that ketamine could stop depression in four hours, proving the problem wasn’t a lack of fuel, but broken wiring. We unpack the science of structural repair: how ketamine blocks the “disappointment center” (the lateral habenula), wakes up the “construction foreman” (mTOR), and releases BDNF (Miracle-Gro for the brain) to physically regrow lost connections. We also look at the macro level, exploring how this “reboot” disrupts the Default Mode Network to stop the loop of rumination. Finally, we discuss where we are today in 2026: the age of Precision Psychiatry, where we stop guessing and start treating the specific biological cause—whether it’s inflammation, glutamate, or connectivity. Reference: Bulek, D., & BaDour, S. (2026). From monoamine deficits to multiscale plasticity: Twenty-five years of ketamine and the neurophysiology of depression. Journal of Neurophysiology. https://doi.org/10.1152/jn.00516.2025 The post The Neuroplastic Revolution appeared first on Talking Ketamine Podcast.

For patients battling the "syndemic" of diabetes, depression, and pain, ketamine offers a potential breakthrough—but can their bodies handle the metabolic chaos of blood sugar spikes, liver "traffic jams," and dangerous hypoglycemic drops?

What does ketamine therapy actually feel like? We pivot from efficacy scores to the patient's lived experience, exploring the emotional journey from desperate hope to the "rollercoaster" of the trip and the vital role of human connection in healing.

A new 2025 review challenges the idea that dissociation is just a "weird side effect" of ketamine, proposing instead that this altered state may be the critical mechanism for brain repair and antidepressant relief.

Is ketamine a "reset button" for the brain or a "relational tool" for the heart? This episode explores how dose defines the therapy, contrasting the rapid relief of high-dose psychedelic experiences with the gentle, integrative power of low-dose psyc

A massive study of 74,000 hospital admissions reveals how early ketamine use can cut hospital stays in half for kids suffering from the excruciating pain of sickle cell disease.

We tackle the #1 patient question by revealing a specific "early warning" marker that appears after just two infusions, while debunking myths about who is eligible for ketamine therapy.

Could your mouth hold the secret to ketamine's power? This episode explores a surprising study linking esketamine's ability to prevent post-surgery sleep disorders with a shift in oral bacteria.

When the brain's "brake pedal" gets stuck, this episode reveals how ketamine might serve as the critical switch to release patients from the life-threatening grip of refractory catatonia.

Learn how a triple-therapy approach, centered on a ketamine infusion, served as a "system reset button" to break the agonizing pain cycle of Complex Regional Pain Syndrome (CRPS) in a young athlete.